Stock VIRACTA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Viracta Therapeutics, Inc. Nasdaq

Equities

US92765F1084

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals Sale of its Priority Review Voucher
AQ
XOMA Receives $8.1 Million Milestone Related to Sale of Priority Review Voucher
MT
Day One Biopharmaceuticals Sells Priority Review Voucher for $108 Million
MT
Oppenheimer Adjusts Price Target on Viracta Therapeutics to $11 From $13, Maintains Outperform Rating
MT
Viracta Therapeutics Announces New Employment Inducement Grants
AQ
Viracta Therapeutics Appoints Michael Faerm CFO
MT
Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer
AQ
Viracta Therapeutics, Inc. Appoints Michael Faerm as Chief Financial Officer
CI
Sunesis: Q1 Earnings Snapshot
AQ
Viracta Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
AQ
Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
AQ
Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive Peripheral T-Cell Lymphoma
AQ
Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma
AQ
Viracta Therapeutics, Inc. Reports Positive Topline Results from Stage 1 of the Pivotal Phase 2 NAVAL-1 Trial
CI
Viracta Therapeutics : HST 2024 – Presentation
PU
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan
AQ
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan
CI
Lenz Therapeutics, Graphite Bio Complete Merger; Combined Company Names New CFO
MT
Viracta Therapeutics, Inc. Announces Executive Changes
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VIRX Stock
  4. Stock
  5. News Viracta Therapeutics, Inc.